trending Market Intelligence /marketintelligence/en/news-insights/trending/TDqX29GzBAJknRWmqqXAYg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Haba Laboratories fiscal Q3 profit climbs YOY

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID 19 Impact Recovery Media Telecom and Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Haba Laboratories fiscal Q3 profit climbs YOY

Haba Laboratories Inc. said its normalized net income for the fiscal third quarter ended Dec. 31, 2015, came to ¥126.15 per share, a gain from ¥15.73 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥496.3 million, an increase from ¥61.9 million in the prior-year period.

The normalized profit margin rose to 12.3% from 1.7% in the year-earlier period.

Total revenue climbed 9.3% on an annual basis to ¥4.03 billion from ¥3.69 billion, and total operating expenses fell 8.4% on an annual basis to ¥3.27 billion from ¥3.58 billion.

Reported net income increased from the prior-year period to ¥508.0 million, or ¥129.14 per share, from ¥136.0 million, or ¥34.57 per share.

As of Feb. 15, US$1 was equivalent to ¥114.50.